Newsfeeds - Spark Newswire

3 minute read

Centessa Pharmaceuticals To Present Additional Data From Open-Label Extension Of Phase 2a Study Of SerpinPC For Hemophilia At The 16th Annual Congress Of The European Association For Haemophilia And Allied Disorders On February 10, 2023

Today, 6:09 AM

Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the Company will present

CNTA

1 minute read

Centessa Pharmaceuticals Q3 EPS $(0.57) Down From $(0.45) YoY

By Benzinga Newsdesk

Today, 6:09 AM

Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.57) per share. This is a 26.67 percent decrease over losses of $(0.45) per share from the same period last year.

CNTA

1 minute read

Centessa Pharmaceuticals Announces Poster Presentation At 26th Conference of the European Sleep Research Society

By Bill Haddad

Today, 6:09 AM

BOSTON and LONDON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced that non-clinical data from its oral orexin receptor 2 (OX2R) agonist discovery pipeline have been

CNTA

3 minute read

Important Biotech Catalysts For September 14, 2022 – End Of The Day Summary

By Ragothaman Srinivasan

Today, 6:09 AM

The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON)…

ADVM

1 minute read

FDA Grants Orphan Drug Status To Centessa’s Hemophilia B Candidate

By Ragothaman Srinivasan

Today, 6:09 AM

Centessa Pharmaceuticals (NASDAQ: CNTA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC for the treatment of hemophilia B. A Phase 2a proof-of-concept study evaluated SerpinPC in severe hemophilia A and B patients not on prophylaxis.

CNTA

1 minute read

Morgan Stanley Downgrades Centessa Pharmaceuticals to Underweight, Lowers Price Target to $5

By Benzinga Newsdesk

Today, 6:09 AM

Morgan Stanley analyst Matthew Harrison downgrades Centessa Pharmaceuticals (NASDAQ:CNTA) from Overweight to Underweight and lowers the price target from $10 to $5.

CNTA

1 minute read

Goldman Sachs Maintains Neutral on Centessa Pharmaceuticals, Lowers Price Target to $4

By Benzinga Newsdesk

Today, 6:09 AM

Goldman Sachs analyst Salveen Richter maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Neutral and lowers the price target from $5 to $4.

CNTA

4 minute read

Biotech Daily: Cancer Causing Impurities In Merck’s Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon’s Monkeypox Trial

By Vandana Singh

Today, 6:09 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ADMP

1 minute read

Centessa Pharmaceuticals Q2 EPS $(0.69) Down From $(0.65) YoY

By Benzinga Newsdesk

Today, 6:09 AM

Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.69) per share. This is a 6.15 percent decrease over losses of $(0.65) per share from the same period last year.

CNTA

1 minute read

Morgan Stanley Maintains Overweight on Centessa Pharmaceuticals, Lowers Price Target to $10

By Benzinga Newsdesk

Today, 6:09 AM

Morgan Stanley analyst Matthew Harrison maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight and lowers the price target from $15 to $10.

CNTA